Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?L?per 10⁶ cells in 100 ?L?volume. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor? 647 has a maximum emission of 668 nm when it is excited at 633nm / 635nm.

ELISA or ELISPOT Detection: The biotinylated MAb11 antibody is useful as the detection antibody in a sandwich ELISA or ELISPOT, when used in conjunction with the purified MAb1 antibody (Cat. No. 502802/502804) as the capture antibody.

Flow Cytometry^3,5,6,10: The fluorochrome-labeled MAb11 antibody is useful for intracellular and membrane-bound immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.

Additional reported applications (for the relevant formats) include: neutralization^1,2, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections⁴ and acetone-fixed frozen tissue sections⁸, immunocytochemistry⁷, and immunofluorescence⁹. The MAb11 antibody can neutralize the bioactivity of natural or recombinant TNF-a.

Note: For testing human TNF-a in serum or plasma, BioLegend's ELISA Max? Sets (Cat. No. 430201 to 430206) are specially developed and recommended. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for neutralization of human TNF-a bioactivity (Cat. No. 502922).

The Purified MAb1 antibody is useful in neutralization² and as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated MAb11 antibody (Cat. No. 502904/502914) as the detecting antibody.

Clone MAb11 cross-reacts to Cat¹¹

1. Rathjen D, et al. 1991. Mol. Immunol. 28:79. (Neut)
2. Ablamunits V, et al. 2010. Eur. J. Immunol. 40:2891. (Neut)
3. Enr quez J, et al. 2002. Adv. Perit. Dial. 18:177. (ICFC)
4. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC)
5. Chen H, et al. 2005. J. Immunol. 175:591. (ICFC)
6. Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed
7. Andersson U, et al. 2000. J. Exp. Med. 192:565. (ICC)
8. Moormann AM, et al. 1999. J. Infect. Dis. 180:1987. (IHC)
9. Zhao XJ, et al. 2003. J. Immunol. 170:2923. (IF)
10. Rieger R, et al. 2009. Cancer Gene Ther. 1:53-64. (FC)
11. Maksaereekul S, et al. 2009. Vaccine. 28:3754 (FC)

1. Franzoni G, et al. 2013. Clin Vaccine Immunol. 20:1604. PubMed
2. Fang F, et al. 2022. JCI Insight. 7:. PubMed
3. Muenchhoff M, et al. 2016. Sci Transl Med. 8: 358ra125. PubMed
4. Lee J, et al. 2020. Sci Rep. 10:17753. PubMed
5. Jacquelot N, et al. 2016. J Invest Dermatol. 136: 994-1001. PubMed
6. Vacaflores A, et al. 2016. PLoS One. 11: 0157175. PubMed
7. Huang RS, et al. 2021. Curr Protoc. 1:e246. PubMed
8. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
9. Ricklin ME, et al. 2017. Sci Rep. 7:16379. PubMed
10. Yin S, et al. 2015. Sci Rep. 5: 14432. PubMed
11. Auray G, et al. 2016. J Immunol. 197(12):4791-4806. PubMed
12. Harris LD, et al. 2020. Front Cell Infect Microbiol. 10:120. PubMed

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. Beutler B, et al. 1988. Annu. Rev. Biochem. 57:505.
3. Beutler B, et al. 1989. Annu. Rev. Immunol. 7:625.
4. Tracey K, et al. 1993. Crit. Care Med. 21:S415.